A Phase 3 interventional study of Oral Treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 135 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-05-10.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one has the largest enrollment, is one of 2 that started in 2007, is one of 14 in phase 3, and was the 13th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2007.
This study's enrollment of 894 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 2nd largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2007, is one of 17 in phase 3, and was the 16th registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308. The study assessed the long term safety of oral treprostinil and the effect of continued treatment with oral treprostinil on exercise capacity after 1 year of treatment.
This was an international, multicenter, open-label study designed to provide oral treprostinil for eligible subjects who participated in Studies TDE-PH-301, TDE-PH-302, TDE-PH-308, TDE-PH-202, TDE PH 203, and TDE-PH-205. Subjects randomly allocated to receive oral treprostinil in Studies TDE-PH-301, TDE-PH-302, or TDE-PH-308 and enrolled in this open-label study completed visits at Months 6, 12, 24, 36, and yearly visits thereafter. Subjects randomly allocated to receive placebo in Studies TDE-PH-301, TDE-PH-302, or TDE-PH-308 completed visits at Months 3, 6, 12, 24, 36, and yearly visits thereafter. Subjects that transitioned from Studies TDE-PH-202, TDE-PH-203, and TDE-PH-205 (that had an open-label study design) followed the regimen for subjects receiving oral treprostinil. A 6-Minute Walk Test (6MWT) and Borg dyspnea score were conducted at the visit which occurred 12 months after the subject's first exposure to oral treprostinil.
Adverse events (AEs) were reported continuously throughout the study; any AEs ongoing at the time of discharge from Studies TDE PH-301, TDE PH-302, TDE-PH-308, TDE-PH-202, TDE-PH-203, and TDE-PH-205 were recorded as AEs and marked as "ongoing from previous study" in the subject's electronic Case Report Form (eCRF). Study drug dosing and pulmonary arterial hypertension (PAH) concomitant medication usage were assessed at each scheduled study visit and recorded in the subject's eCRF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects from previous studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405), TDE-PH-301 (NCT00325442), TDE-PH-302 (NCT00325403), or TDE PH-308 (NCT00887978). Subjects were instructed to take the appropriate amount of 0.125, 0.25, 0.5, 1, and/or 2.5 mg tablets based upon their prescribed dose. Investigators were instructed to increase the dose of oral treprostinil in the absence of dose limiting drug-related AEs to ensure each subject received the optimal clinical dose throughout the study
Drug: Oral Treprostinil
Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
Also known as: Treprostinil diethanolamine, treprostinil diolamine, UT-15C
Change in Exercise Capacity at Month 12
Assess the effect of continued therapy with oral treprostinil on exercise capacity as assessed by the change from Baseline in 6-Minute Walk Test (6MWT) after 1 year of treatment. The 6MWT is the clinical standard for assessing subject functional status in the treatment of PAH and has been considered an objective measure of subject functional status by the American Thoracic Society. The distance a subject can walk in 6 minutes is recorded in meters.
Time frame: From First Visit (Visit 1) to Month 12
Baseline values for demographic parameters were defined and collected in the same manner for subjects who received either placebo or oral treprostinil in the preceding studies. Note that Studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405) had an open-label design; therefore, all Baseline demographic parameters were based on values collected at the time of enrollment in the previous study.
| Milestone | Oral Treprostinil |
|---|---|
| Started | 894 |
| Completed | 208 |
| Not completed | 686 |
| Withdrew: Death | 174 |
| Withdrew: Progressive disease | 163 |
| Withdrew: Adverse event | 172 |
| Withdrew: Withdrawal by subject | 113 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Protocol violation | 13 |
| Withdrew: Pi decision | 8 |
| Withdrew: Limited study drug effectiveness | 7 |
| Withdrew: Non-compliance with study procedures | 7 |
| Withdrew: Lung transplant | 5 |
| Withdrew: Unable to tolerate study drug | 2 |
| Withdrew: Use of excluded medication | 2 |
| Withdrew: Patient self-discontinuation | 1 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Surgery | 1 |
Assess the effect of continued therapy with oral treprostinil on exercise capacity as assessed by the change from Baseline in 6-Minute Walk Test (6MWT) after 1 year of treatment. The 6MWT is the clinical standard for assessing subject functional status in the treatment of PAH and has been considered an objective measure of subject functional status by the American Thoracic Society. The distance a subject can walk in 6 minutes is recorded in meters.
| meters | Oral Treprostinil |
|---|---|
| Change in Exercise Capacity at Month 12 | 22.0 (-345.0 to 282.0) |
Collected over From the time of subject enrollment until exit from the study (up to 13 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Treprostinil | 174/894 (19.5%) | 547/894 (61.2%) | 890/894 (99.6%) |
| Event | Oral Treprostinil |
|---|---|
| Pulmonary HypertensionRespiratory, thoracic and mediastinal disorders | 129/894 |
| Right ventricular failureCardiac disorders | 129/894 |
| PneumoniaInfections and infestations | 63/894 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 41/894 |
| Acute kidney injuryRenal and urinary disorders | 37/894 |
| Cardiac failureCardiac disorders | 36/894 |
| SyncopeNervous system disorders | 30/894 |
| AnaemiaBlood and lymphatic system disorders | 28/894 |
| Chest painGeneral disorders | 28/894 |
| HypotensionVascular disorders | 23/894 |
| Event | Oral Treprostinil |
|---|---|
| HeadacheNervous system disorders | 698/894 |
| DiarrhoeaGastrointestinal disorders | 592/894 |
| NauseaGastrointestinal disorders | 505/894 |
| FlushingVascular disorders | 416/894 |
| VomitingGastrointestinal disorders | 349/894 |
| Pain in jawMusculoskeletal and connective tissue disorders | 313/894 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 255/894 |
| DizzinessCardiac disorders | 248/894 |
| Upper respiratory tract infectionInfections and infestations | 222/894 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 207/894 |
All subjects enrolled in the study.
| Age, Continuous(years) | Oral Treprostinil |
|---|---|
| Mean | 47.7 (12 to 80) |
| Sex: Female, Male(Participants) | Oral Treprostinil |
|---|---|
| Female | 696 |
| Male | 198 |
| Ethnicity (NIH/OMB)(Participants) | Oral Treprostinil |
|---|---|
| Hispanic or Latino | 83 |
| Not Hispanic or Latino | 809 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Oral Treprostinil |
|---|---|
| American Indian or Alaska Native | 34 |
| Asian | 219 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 46 |
| White | 589 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Region of Enrollment(participants) | Oral Treprostinil |
|---|---|
| Puerto Rico | 1 |
| United States | 436 |
| United Kingdom | 27 |
| Portugal | 1 |
| India | 79 |
| Spain | 6 |
| Canada | 19 |
| Austria | 7 |
| Netherlands | 15 |
| Sweden | 2 |
| Belgium | 6 |
| Ireland | 2 |
| Poland | 16 |
| Italy | 13 |
| Mexico | 38 |
| Israel | 22 |
| Australia | 44 |
| France | 22 |
| Germany | 14 |
| China | 124 |
| PAH Etiology(Participants) | Oral Treprostinil |
|---|---|
| Idiopathic Pulmonary Arterial Hypertension/ Heritable Pulmonary Arterial Hypertension | 608 |
| Collagen Vascular Disease | 224 |
| Other | 60 |
| Missing | 2 |
| World Health Organization (WHO) Functional Class(Participants) | Oral Treprostinil |
|---|---|
| I | 18 |
| II | 298 |
| III | 527 |
| IV | 11 |
| Missing | 40 |
Showing the first 100 of 135 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2007 to primary completion in Feb 2020, 156 months.
Results were first posted in May 2021, 1 year 2 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 156 months is above that.
Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →